LKFT Stock Analysis: LAKEFRONT BIOTHERAPEUTICS | AS
Biotechnology | AS, Netherlands | Market Cap: 1.730m EUR | 12M Return: 9.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.10M
Qual. Beats: 0
Rev. Trend: 90.4%
Warnings
Tailwinds
Seasonality 0.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Lakefront Biotherapeutics NV is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, developing therapies in oncology and immunology for the U.S. and European markets. Originally incorporated in 1999 as Galapagos NV, the company rebranded in May 2026 and trades on the AS exchange under the ticker LKFT, with a small-cap market capitalization of approximately $1.97 billion USD.
Its pipeline consists of three early- to mid-stage product candidates. GLPG3667 is in a Phase 2 trial for dermatomyositis and systemic lupus erythematosus. GLPG5101 (a CD19 CAR-T candidate) and GLPG5301 (a BCMA CAR-T candidate) are both manufactured at point of care and are currently in Phase 1/2 trials for relapsed/refractory non-Hodgkin lymphoma and multiple myeloma, respectively.
Lakefront maintains a collaboration agreement with Gilead Sciences, Inc. CAR-T therapies are a form of cell therapy in which a patients own T cells are engineered to target cancer, and the point-of-care manufacturing model is designed to shorten the vein-to-vein time typically associated with centralized production. As a clinical-stage company with no marketed products disclosed, the business model depends on advancing pipeline candidates through clinical development and regulatory milestones, with revenue largely driven by collaboration agreements rather than product sales.
- Phase 2 GLPG3667 data readout in dermatomyositis imminent
- Gilead collaboration advances CAR-T pipeline development
- Cash burn from late-stage trials pressures small-cap balance sheet
| Net Income: 488.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 1.07 > 1.0 |
| NWC/Revenue: 283.6% < 20% (prev 1.10k%; Δ -817.5% < -1%) |
| CFO/TA -0.09 > 3% & CFO -292.4m > Net Income 488.8m |
| Net Debt (-2.98b) to EBITDA (432.1m): -6.89 < 3 |
| Current Ratio: 30.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.0m) vs 12m ago 4.72% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 28.23% > 50% (prev 6.85%; Δ 21.38% > 0%) |
| Interest Coverage Ratio: 171.3 > 6 (EBIT TTM 380.2m / Interest Expense TTM 2.22m) |
| A: 0.88 (Total Current Assets 3.06b - Total Current Liabilities 100.4m) / Total Assets 3.37b |
| B: 0.07 (Retained Earnings 228.3m / Total Assets 3.37b) |
| C: 0.10 (EBIT TTM 380.2m / Avg Total Assets 3.70b) |
| D: 27.33 (Book Value of Equity 3.25b / Total Liabilities 119.1m) |
| Altman-Z'' = 35.36 = AAA |
| DSRI: 0.28 (Receivables 54.0m/51.1m, Revenue 1.04b/275.6m) |
| GMI: 0.89 (GM 87.35% / 98.01%) |
| AQI: 0.64 (AQ_t 0.07 / AQ_t-1 0.11) |
| SGI: 3.79 (Revenue 1.04b / 275.6m) |
| TATA: 0.23 (NI 488.8m - CFO -292.4m) / TA 3.37b) |
| Beneish M = -1.91 (Cap -4..+1) = B |
As of July 08, 2026, the stock is trading at EUR 26.86 with a total of 65,193 shares traded. Over the past week, the price has changed by +4.51%, over one month by +10.26%, over three months by +9.54% and over the past year by +9.54%.
Current recommended Stop Loss: 25.70 (which is 4.3% or 1.7 ATR below the current price).
LAKEFRONT BIOTHERAPEUTICS has no consensus analysts rating.
P/E Trailing = 3.5547
P/E Forward = 357.1429
P/S = 1.6579
P/B = 0.525
Revenue TTM = 1.04b EUR
EBIT TTM = 380.2m EUR
EBITDA TTM = 432.1m EUR
Long Term Debt = 4.85m EUR (estimated: total debt 6.43m - short term 1.58m)
Short Term Debt = 1.58m EUR (from shortTermDebt, last quarter)
Debt = 6.43m EUR (from shortLongTermDebtTotal, last quarter) (leases 6.43m already included)
Net Debt = -2.98b EUR (calculated: Debt 6.43m - CCE 2.98b)
Enterprise Value = 1.73b EUR (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = 171.3 (Ebit TTM 380.2m / Interest Expense TTM 2.22m)
EV/FCF = -5.75x (Enterprise Value 1.73b / FCF TTM -301.1m)
FCF Yield = -17.40% (FCF TTM -301.1m / Enterprise Value 1.73b)
FCF Margin = -28.85% (FCF TTM -301.1m / Revenue TTM 1.04b)
Net Margin = 46.83% (Net Income TTM 488.8m / Revenue TTM 1.04b)
Gross Margin = unknown ((Revenue TTM 1.04b - Cost of Revenue TTM 20.8m) / Revenue TTM)
Tobins Q-Ratio = 0.51 (Enterprise Value 1.73b / Total Assets 3.37b)
Interest Expense / Debt = 34.50% (Interest Expense 2.22m / Debt 6.43m)
Taxrate = 0.50% (70.0k / 14.0m)
NOPAT = 378.3m (EBIT 380.2m * (1 - 0.50%))
Current Ratio = 30.48 (Total Current Assets 3.06b / Total Current Liabilities 100.4m)
Debt / Equity = 0.00 (Debt 6.43m / totalStockholderEquity, last quarter 3.25b)
Debt / EBITDA = -6.89 (Net Debt -2.98b / EBITDA 432.1m)
Debt / FCF = 9.88 (negative FCF - burning cash) (Net Debt -2.98b / FCF TTM -301.1m)
Total Stockholder Equity = 2.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.22% (Net Income 488.8m / Total Assets 3.37b)
RoE = 16.88% (Net Income TTM 488.8m / Total Stockholder Equity 2.90b)
RoCE = 13.11% (EBIT 380.2m / Capital Employed (Equity 2.90b + L.T.Debt 4.85m))
RoIC = 11.74% (NOPAT 378.3m / Invested Capital 3.22b)
WACC = 5.12% (E(1.73b)/V(1.74b) * Re(5.01%) + D(6.43m)/V(1.74b) * Rd(34.50%) * (1-Tc(0.01)))
Discount Rate = 5.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 10.54 | Cagr: 4.72%
[DCF] Fair Price = unknown (Cash Flow -301.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.25 | # QB: 0
Revenue Correlation: 90.42 | Revenue CAGR: 115.4% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.43 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.43 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-2.87 | Chg30d=-12.78% | Revisions=-50% | GrowthEPS=-128.1% | GrowthRev=-86.5%
EPS next Year (2027-12-31): EPS=-4.01 | Chg30d=-14.48% | Revisions=-25% | GrowthEPS=-40.0% | GrowthRev=-12.2%
[Analyst] Revisions Ratio: -57% (up=0, down=4)